Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06367998

Effect of Pregabalin on Shoulder Pain in Patients With Central Sensitization After Arthroscopic Rotator Cuff Repair

The Effect of Pregabalin on Shoulder Pain of Patients With Myofascial Pain Syndrome and Central Sensitization Who Undergo Arthroscopic Rotator Cuff Repair

Status
Not Yet Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
76 (estimated)
Sponsor
The Catholic University of Korea · Academic / Other
Sex
All
Age
20 Years – 69 Years
Healthy volunteers
Accepted

Summary

This study aims to investigate the effects of Pregabalin intake on shoulder pain management in patients with central sensitization undergoing arthroscopic rotator cuff repair. Although Pregabalin is known to be effective in controlling pain after shoulder arthroscopy, research on its efficacy in pain management for patients with central sensitization is scarce. Utilizing a list that identifies central sensitization, this study will explore whether Pregabalin can reduce postoperative pain in these patients and potentially improve joint mobility, emotional, and physical functioning. A prospective randomized study is planned, with inclusion criteria set for patients aged between 19 and 70 who have undergone arthroscopic rotator cuff repair. The study will compare clinical outcomes up to one year postoperatively between two groups of 38 patients each. The case group will receive standard postoperative medications (NSAIDs) plus Pregabalin oral intake from the day before surgery to six weeks postoperatively, while the control group will receive only the standard postoperative medications without Pregabalin.

Conditions

Interventions

TypeNameDescription
DRUGPregabalinPregabalin oral intake from the day before surgery to six weeks postoperatively

Timeline

Start date
2024-09-01
Primary completion
2025-05-01
Completion
2026-05-01
First posted
2024-04-16
Last updated
2024-08-23

Source: ClinicalTrials.gov record NCT06367998. Inclusion in this directory is not an endorsement.